Shenzhen Hengtai Huasheng Asset Management
Shenzhenhths-capital.com
Overview
Shenzhen Hengtai Huasheng Asset Management is a Chinese asset management firm founded in 2013. The firm's primary investment areas include healthcare, consumer upgrades, new energy, and smart manufacturing, engaging in equity investment, M&A, industrial consolidation, and secondary market investments.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| SpinQ | Apr 2026 | Series C Extension | Co-investor |
| SpinQ | Jan 2026 | Series C | Lead |
| WestVac Biopharma Co., Ltd. | Apr 2021 | Series B | Co-investor |
| WestGene Biopharma | Apr 2021 | Series B | Co-investor |
| Hryz Bio Tech | Sep 2020 | Series A Extension | Co-investor |
Key People
伍秀婷
合伙人 Partner 总经理 General Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
